(Total Views: 192)
Posted On: 01/07/2017 6:40:03 PM
Post# of 72447
I think a big reason a partner didn't step up for Absssi is because a generic version of Cubicin (Dapto) has already been approved by the FDA and at least one of it's patents expires September 24, 2019;
Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
So with the probability that Dapto is going generic before B Absssi would be approved, and no guarantee that they wont come up with an oral formulation for it, I think it was wise to go with B-OM and B-UP and with P until the coffers can afford a longer term and expensive PIII trial. K will need some nurturing as well but my confidence is high with the new highers and I'm comfortable with our starting lineup.
Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
So with the probability that Dapto is going generic before B Absssi would be approved, and no guarantee that they wont come up with an oral formulation for it, I think it was wise to go with B-OM and B-UP and with P until the coffers can afford a longer term and expensive PIII trial. K will need some nurturing as well but my confidence is high with the new highers and I'm comfortable with our starting lineup.
(0)
(0)
